Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Wool

Obstetrics & Gynecology Westfield, MA Medical Doctor

NPI 1568467132 CMS profile 116709

65 Springfield Rd, Ste 2, Westfield, MA 01085

Open in the dashboard

General payments

$3,149

142 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Wool of Westfield, MA is reported in the CMS Open Payments database as having received $3,149 across 142 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $581 25
2024 General $376 13
2023 General $293 10
2022 General $174 8
2021 General $225 13
2020 General $450 24
2019 General $1,048 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Wool
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Robert Wool were reported at $581. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Robert Wool Obstetrics & Gynecology median Middle half National median
2019 $1,048 $172 $62–$391 $163
2020 $450 $94 $36–$222 $114
2021 $225 $136 $42–$369 $132
2022 $174 $160 $50–$433 $149
2023 $293 $169 $56–$423 $160
2024 $376 $152 $50–$371 $164
2025 $581 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $653 33 payments
  2. AbbVie, Inc. $599 25 payments
  3. Astellas Pharma US Inc $415 11 payments
  4. TherapeuticsMD, Inc. $275 18 payments
  5. Sumitomo Pharma America, Inc. $271 11 payments
  6. Exeltis, USA Inc. $121 6 payments
  7. Exact Sciences Corporation $113 5 payments
  8. Allergan Inc. $113 6 payments
  9. Organon LLC $106 5 payments
  10. Sage Therapeutics, Inc. $68 3 payments
  11. Other $415 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,898 137 payments
  2. Education $251 5 payments
Products named General payments · program years 2019–2025
  1. Prolia $653 33 payments
  2. Orilissa Endocrinology $340 10 payments
  3. LO LOESTRIN FE $299 16 payments
  4. EVENITY $280 17 payments
  5. GEMTESA $271 11 payments
  6. Veozah $222 9 payments
  7. BIJUVA $124 9 payments
  8. NEXPLANON $106 5 payments
  9. Cologuard Collection Kit $89 4 payments
  10. ORILISSA Womens Health $78 5 payments
  11. Other $990 51 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

4,733

Median for Obstetrics & Gynecology: 65

Drug cost

$1,088,197

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

93.8%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Arexvy Rsvpref3 Antigen/As01e/Pf Brand 2,177 $657,637
Shingrix Varicella-Zoster Ge/As01b/Pf Brand 1,414 $303,799
Abrysvo Rsv Vacc, Pref A And Pref B/Pf Brand 178 $54,866
Boostrix Tdap Diphth,pertuss(Acell),tet Vac Brand 518 $34,748
Prolia Denosumab Brand 13 $22,414
Estradiol-Norethindrone Acetat Estradiol/Norethindrone Acet Brand 43 $3,331
Prempro Estrogen,con/M-Progest Acet Brand 12 $2,851
Estradiol Generic 118 $2,691
Valacyclovir Valacyclovir Hcl Brand 31 $1,198
Alendronate Sodium Generic 106 $1,160

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$89,675

Of which drugs: $64,905

Medicare patients

188

Average age 71

Services billed

3,792

188 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 48%
Osteoporosis 40%
Depression 26%
Chronic kidney disease 15%
Diabetes 13%
COPD 13%
Cancer 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 36 3,241 $64,905

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $95
$95 — —
Veozah
  • Astellas Pharma US Inc $48
$48 — —
EVENITY
  • Amgen Inc. $28
$28 — —
Prolia
  • Amgen Inc. $28
$28 13 3,241
ABRYSVO
  • PFIZER INC. $28
$28 178 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

142 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record